This may indicate an intrinsic CLL-cell resistance to apoptosis in the presence of IgRT and is perhaps supportive role of BTKi therapy as opposed to BCL-2 inhibition in CLL patients treated with IgRT. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.